Electromedical Technologies EBITDA per Share
EBITDA per Share of Electromedical Technologies (EMED) as of Nov 2, 2026.
Get this data via API
Financial Data API
EBITDA per Share
-0.00USD
YoY
-75.82%
Last updated:
EBITDA per Share of Electromedical Technologies is 2025 -0.00 USD. EBITDA per Share of Electromedical Technologies was 2024 -0.00 USD. It decreases by -75.82% higher compared to the previous year.
The Electromedical Technologies EBITDA per Share history
3 Years
10 Years
25 Years
Max
EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.02 USD
Jan 1, 2019
-0.10 USD
Jan 1, 2020
-0.14 USD
Jan 1, 2021
-0.07 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
-0.00 USD
| YEAR | EBITDA per Share | YoY |
|---|---|---|
| -0.00USD | -75.82% | |
| -0.00USD | -74.66% | |
| -0.00USD | -46.64% | |
| -0.01USD | -88.01% | |
| -0.07USD | -51.65% | |
| -0.14USD | +43.72% | |
| -0.10USD | +448.70% | |
| -0.02USD | -40.12% | |
| -0.03USD | +220.12% | |
| -0.01USD | -35.13% | |
| -0.01USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Electromedical Technologies Stock analysis
What does Electromedical Technologies do? Electromedical Technologies, Inc. generates revenue through the sale of medical devices for pain management, specifically targeting consumers and healthcare professionals. The company's primary products include WellnessPro Plus, WellnessPro POD, and Wellness ION Pen, which utilize bioelectronics and electrical impulses to alleviate pain without drugs. WellnessPro Plus functions as a prescription device that mimics the body's electric signals with micro-current stimulation, while the Wellness ION Pen delivers targeted frequency stimulation via interferential cold laser technology. These products are designed for both consumer and professional use in chronic and acute pain relief.
The company focuses on developing electronic medicine solutions that combine micro-stimulation with expanded wavelength capabilities, particularly through the Wellness ION Pen, which is intended for over-the-counter sales. WellnessPro POD is part of the product lineup but lacks detailed description in the business description. The target segments are consumers seeking non-drug pain relief and healthcare professionals who prescribe or recommend these devices for pain management.
Electromedical Technologies, Inc. markets its products under the WellnessPro and Wellness ION Pen brand names, emphasizing their unique bioelectronics approach. The company's revenue streams are derived from direct sales of these devices, with WellnessPro Plus positioned as an intelligent therapy device for both home and clinical use. The Wellness ION Pen's over-the-counter availability expands its market reach to general consumers who prefer non-prescription pain management solutions. Electromedical Technologies is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Electromedical Technologies stock
On Eulerpool you can find the complete historical development of EBITDA per Share Electromedical Technologies since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Electromedical Technologies
All Key Metrics — Electromedical Technologies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth